In a nutshell Drugs commonly used to treat HIV and hepatitis B (called NRTIs) were found to reduce the risk of developing ...

Additionally, the researchers found that mice deficient in Gasdermin D experienced less severe disease than control mice. The researchers said it's currently unknown which components of the ...

NASH — renamed metabolic dysfunction-associated steatotic liver disease in 2023 — affects nearly 7% of the ... This occurred ...

Researchers have uncovered new insights into the mechanisms behind severe schistosomiasis, focusing on how immune responses triggered by the parasite's eggs contribute to inflammation. The findings ...

Yes-associated protein (YAP) is a core effector molecule of the Hippo signaling pathway, which regulates transcription and controls cell proliferation and growth. However, the role of YAP in ...

VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 ...

RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, ...

Ventus' pipeline also includes a centrally-acting NLRP3 drug (VENT-02) for diseases characterised by neuroinflammation and neurodegeneration, and another peripherally-acting drug (VENT-05) for ...

Ventyx Biosciences, Inc.’s VTYX share price has dipped by 6.88%, which has investors questioning if this is right time to buy ...

The researchers found that the activation of NLRP3 and AIM2 inflammasomes—proteins ... This species causes the intestinal and hepatic form of the disease, which results in various ...